{"id":"dtg-3tc-fdc","safety":{"commonSideEffects":[{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Rash"}]},"_chembl":{"chemblId":"CHEMBL4175547","moleculeType":"Small molecule","molecularWeight":"243.34"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This fixed-dose combination (FDC) pairs two antiretroviral agents with complementary mechanisms. Dolutegravir is an integrase strand transfer inhibitor (INSTI) that prevents HIV from integrating into the host genome. Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) that terminates DNA chain elongation during reverse transcription. Together, they provide dual suppression of HIV replication at different stages of the viral lifecycle.","oneSentence":"DTG (dolutegravir) inhibits HIV integrase to prevent viral replication, while 3TC (lamivudine) inhibits reverse transcriptase to block HIV from converting its RNA genome into DNA.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:10:10.121Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection in treatment-naïve and treatment-experienced adults"},{"name":"HIV-1 infection in adolescents and children (age and weight-dependent formulations)"}]},"trialDetails":[{"nctId":"NCT06337032","phase":"PHASE4","title":"A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-08-27","conditions":"HIV-1-infection","enrollment":350},{"nctId":"NCT07202546","phase":"PHASE2","title":"A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)","status":"RECRUITING","sponsor":"ViiV Healthcare","startDate":"2026-02-11","conditions":"HIV Infections","enrollment":150},{"nctId":"NCT05917509","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2023-07-06","conditions":"HIV Infections","enrollment":171},{"nctId":"NCT03682848","phase":"PHASE3","title":"Safety and Efficacy of Dolutegravir/Lamivudine (DTG/3TC) in Therapy-naive Human Immunodeficiency Virus-1 (HIV-1) Infected Adolescents","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2019-05-06","conditions":"HIV Infections","enrollment":32},{"nctId":"NCT05979311","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2024-02-09","conditions":"HIV, HIV Infections","enrollment":473},{"nctId":"NCT05911360","phase":"PHASE3","title":"A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2023-01-31","conditions":"HIV, HIV Infections","enrollment":205},{"nctId":"NCT05502341","phase":"PHASE2, PHASE3","title":"Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2022-08-16","conditions":"HIV-1-infection","enrollment":689},{"nctId":"NCT06497465","phase":"PHASE3","title":"Dolutegravir/Lamivudine Dual Therapy for ART-naïve People With HIV and TB Receiving Rifampin-based TB Treatment","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2025-09-18","conditions":"Tuberculosis, HIV","enrollment":150},{"nctId":"NCT04880395","phase":"PHASE4","title":"Dolutegravir-Lamivudine for naïve HIV-Infected Patients With ≤200 CD4/mm3","status":"COMPLETED","sponsor":"Fundación Huésped","startDate":"2021-05-17","conditions":"HIV-1-infection","enrollment":265},{"nctId":"NCT06928090","phase":"","title":"Efficacy and Safety of DTG/3TC in Treatment-naïve HIV-1 Infected Patients","status":"ENROLLING_BY_INVITATION","sponsor":"Chungnam National University Hospital","startDate":"2025-01-24","conditions":"HIV","enrollment":200},{"nctId":"NCT04585737","phase":"PHASE4","title":"Efficacy of Switching to DTG/3TC in Virologically-suppressed Adults Currently on B/F/TAF","status":"COMPLETED","sponsor":"Charlotte-Paige Rolle, MD","startDate":"2020-10-05","conditions":"HIV I Infection","enrollment":222},{"nctId":"NCT01910402","phase":"PHASE3","title":"A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA)","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2013-08-22","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":499},{"nctId":"NCT02831764","phase":"PHASE3","title":"An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Participants (Gemini 2)","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2016-07-18","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":722},{"nctId":"NCT04021290","phase":"PHASE3","title":"Regimen Switch to Dolutegravir/Lamivudine Fixed Dose Combination From Current Antiretroviral Regimen in HIV-1 Infected and Virologically Suppressed Adults (SALSA)","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2019-11-11","conditions":"HIV Infections","enrollment":493},{"nctId":"NCT04808973","phase":"PHASE3","title":"DTG Plus 3TC for Prophylaxis of Mother-to-child Transmission of HIV Infection in Pregnant Women","status":"COMPLETED","sponsor":"Fundação Bahiana de Infectologia","startDate":"2021-07-01","conditions":"HIV Infections, Pregnancy Related, Mother to Child Transmission","enrollment":20},{"nctId":"NCT05735535","phase":"PHASE3","title":"Women in Dual With Dolutegravir","status":"UNKNOWN","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2023-10-01","conditions":"HIV Infections","enrollment":290},{"nctId":"NCT02831673","phase":"PHASE3","title":"An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2016-07-21","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":719},{"nctId":"NCT04827134","phase":"PHASE1","title":"A Food-effect Study of the Pediatric Dispersible Tablet Formulations of TRIUMEQ® and DOVATO® in Healthy Adult Participants","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2021-05-07","conditions":"HIV Infections","enrollment":33},{"nctId":"NCT03656783","phase":"PHASE3","title":"Effects of Biktarvy on CFR in Stable HIV Patients","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2018-09-14","conditions":"HIV","enrollment":25},{"nctId":"NCT02075593","phase":"PHASE3","title":"ING200336, Pharmacokinetic and Safety Study in Pregnant Women With Human Immuno Virus Infection","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2014-12-17","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections, Arthralgia","enrollment":4},{"nctId":"NCT02384395","phase":"NA","title":"Safety and Efficacy of Fixed Dose Combination Dolutegravir/Abacavir/Lamivudine FDC Initiated During Acute HIV Infection","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2015-09","conditions":"HIV, Acute HIV Infection","enrollment":40},{"nctId":"NCT03945981","phase":"PHASE3","title":"Rapid Test and Treat Dolutegravir Plus Lamivudine Study in Newly Diagnosed Human Immunodeficiency Virus (HIV)-1 Infected Adults","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2019-07-02","conditions":"HIV Infections","enrollment":131},{"nctId":"NCT03631732","phase":"PHASE3","title":"Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2018-08-28","conditions":"HIV-1 Infection","enrollment":496},{"nctId":"NCT02777229","phase":"PHASE3","title":"Efficacy and Safety of a Dolutegravir-based Regimen for the Initial Management of HIV Infected Adults in Resource-limited Settings","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2016-07","conditions":"HIV-1 Infection","enrollment":616},{"nctId":"NCT03549689","phase":"PHASE2","title":"Effect of Reducing Nucleotide Exposure on Bone Health (ReNew)","status":"WITHDRAWN","sponsor":"Philip Grant","startDate":"2019-08-01","conditions":"HIV/AIDS, HIV-1-infection, Osteopenia","enrollment":""},{"nctId":"NCT02603120","phase":"PHASE3","title":"Safety and Efficacy of Switching From Dolutegravir and ABC/3TC or ABC/DTG/3TC to B/F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-11-11","conditions":"HIV-1 Infection","enrollment":567},{"nctId":"NCT02616029","phase":"PHASE3","title":"Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-17","conditions":"HIV-1 Infection","enrollment":66},{"nctId":"NCT02616783","phase":"PHASE3","title":"Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-22","conditions":"HIV-1 Infection","enrollment":167},{"nctId":"NCT03441984","phase":"PHASE1","title":"To Assess the Relative Bioavailability (BA) of TRIUMEQ® and Dolutegravir and Lamivudine (DTG/3TC) Pediatric Dispersible Tablet Formulations in Healthy Volunteers","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2018-02-26","conditions":"HIV Infections","enrollment":36},{"nctId":"NCT02469246","phase":"PHASE3","title":"Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-06-29","conditions":"HIV-1 Infection","enrollment":567},{"nctId":"NCT03078556","phase":"PHASE1","title":"Bioequivalence Study of Fixed Dose Versus Single Entities of Dolutegravir and Lamivudine","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2017-03-27","conditions":"Infection, Human Immunodeficiency Virus","enrollment":154},{"nctId":"NCT02605954","phase":"PHASE3","title":"Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-11-18","conditions":"HIV-1 Infection","enrollment":275},{"nctId":"NCT02893488","phase":"PHASE1","title":"Relative Bioavailability Study of a Fixed-dose Combination Dolutegravir/Abacavir/Lamivudine Dispersible Tablet","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2016-09-01","conditions":"Infection, Human Immunodeficiency Virus","enrollment":20},{"nctId":"NCT02738931","phase":"PHASE1","title":"Relative Bio-availability Study of Dolutegravir and Lamivudine Fixed Dose Combinations","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2016-05","conditions":"Infection, Human Immunodeficiency Virus","enrollment":30},{"nctId":"NCT02105987","phase":"PHASE3","title":"A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2014-04","conditions":"Infection, Human Immunodeficiency Virus","enrollment":555},{"nctId":"NCT02539576","phase":"PHASE1","title":"Pharmacokinetics, Safety and Tolerability Study of Abacavir/ Dolutegravir/ Lamivudine Fixed-dose Combination Tablets in Healthy Japanese Subjects","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2015-10","conditions":"Infection, Human Immunodeficiency Virus","enrollment":12}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"DTG + 3TC FDC","genericName":"DTG + 3TC FDC","companyName":"ViiV Healthcare","companyId":"viiv-healthcare","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DTG (dolutegravir) inhibits HIV integrase to prevent viral replication, while 3TC (lamivudine) inhibits reverse transcriptase to block HIV from converting its RNA genome into DNA. Used for HIV-1 infection in treatment-naïve and treatment-experienced adults, HIV-1 infection in adolescents and children (age and weight-dependent formulations).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}